SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,684,885 | -60.2% | 81,870 | -9.0% | 0.03% | -65.3% |
Q2 2023 | $4,231,800 | +68.1% | 90,000 | +50.0% | 0.08% | +56.2% |
Q1 2023 | $2,517,600 | +190.0% | 60,000 | +123.4% | 0.05% | +300.0% |
Q2 2022 | $868,000 | -85.9% | 26,862 | -85.6% | 0.01% | -84.0% |
Q1 2022 | $6,161,000 | -58.7% | 186,097 | -46.9% | 0.08% | -55.1% |
Q4 2021 | $14,915,000 | +381.0% | 350,621 | +400.9% | 0.17% | +377.1% |
Q3 2021 | $3,101,000 | -88.9% | 70,000 | -85.7% | 0.04% | -90.4% |
Q2 2021 | $27,826,000 | +550.9% | 489,800 | +757.3% | 0.36% | +298.9% |
Q1 2021 | $4,275,000 | +644.8% | 57,130 | +185.6% | 0.09% | +184.4% |
Q1 2020 | $574,000 | -97.0% | 20,000 | -92.5% | 0.03% | -95.0% |
Q4 2019 | $19,151,000 | +26.4% | 265,300 | +145.6% | 0.64% | -18.4% |
Q3 2019 | $15,151,000 | +22.4% | 108,000 | +59.8% | 0.79% | +26.5% |
Q2 2019 | $12,377,000 | +7.2% | 67,600 | -6.9% | 0.62% | -2.2% |
Q1 2019 | $11,546,000 | +34.2% | 72,600 | -19.2% | 0.64% | -7.3% |
Q4 2018 | $8,606,000 | – | 89,850 | – | 0.69% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |